Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance

Stock Track07-29

Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.

The company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.

The positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197626086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197626086","market":"nz","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance","media":"Stock Track","content":"<p>Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.</p>\n        <p>The company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.</p>\n        <p>The positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-29 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.</p>\n        <p>The company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.</p>\n        <p>The positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1197626086","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197626086","pubTimestamp":1785323449,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.         The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"股票跟踪 | 梯瓦制药在第二季度收入预期和指引的盘前交易中飙升 5.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.\nThe company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.\nThe positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197626086","isCrawlerRequest":true}